Recovery & Repair
Gut and inflammation reset
An anti-inflammatory tripeptide used to support gut health, skin and immune balance.
Ships as a freeze-dried powder. Need water to mix it? Add Reconstitution Solution.
The science
Evidence level
1/5
Preclinical
Cell and animal inflammation research; KPV has not been tested in controlled human trials.
100%2
of KPV-treated mice rescued from death in a severe colitis model
Nanomolar1
concentrations that blocked NF-κB and MAP kinase inflammatory signalling
2 of 22
mouse colitis models where KPV sped recovery and reduced inflammation
Mechanism of action
Targets & pathways
The intestinal peptide transporter PepT1 carries KPV into epithelial and immune cells, so it acts from inside the cell1.
At nanomolar concentrations, KPV inhibited NF-κB and MAP kinase activation and reduced pro-inflammatory cytokine secretion1.
Mechanistic work found KPV acts mainly by inhibiting IL-1β functions rather than through the melanocortin receptors full α-MSH uses3.
In DSS and T-cell transfer colitis, KPV-treated mice recovered earlier, regained weight and showed less inflammatory infiltration and MPO activity2.
What the research shows
Across two mouse models, KPV led to earlier recovery, stronger weight regain and reduced tissue inflammation.
In mice lacking functional MC1R, KPV rescued every treated animal from death during DSS colitis.
Human keratinocytes responded rapidly to KPV across a wide concentration range, showing activity beyond the gut.
Hyaluronic-acid nanoparticles carried KPV to inflamed colon tissue in mice and improved colitis outcomes.
Engineered oral KPV nanoparticles improved delivery and inflammation-model outcomes in mice.
Orally Targeted Delivery of Tripeptide KPV via Hyaluronic Acid-Functionalized Nanoparticles Efficiently Alleviates Ulcerative Colitis.
Molecular therapy : the journal of the American Society of Gene Therapy · 2017
PubMed ↗ (opens in a new tab)Cell and 2 mouse colitis-model experiments linked PepT1-mediated KPV uptake to reduced NF-kB/MAP kinase signalling.
PepT1-mediated tripeptide KPV uptake reduces intestinal inflammation.
Gastroenterology · 2008
PubMed ↗ (opens in a new tab)Mouse intestinal-inflammation models showed lower inflammatory injury, including effects with impaired MC1R signalling.
Melanocortin-derived tripeptide KPV has anti-inflammatory potential in murine models of inflammatory bowel disease.
Inflammatory bowel diseases · 2008
PubMed ↗ (opens in a new tab)Questions
KPV’s cited work emphasizes inflammatory signalling and transporter-mediated uptake; BPC-157 has broader repair-related models. Neither has established controlled human gut-healing efficacy here.
The cited research distinguishes KPV from classical melanocortin agonists; a tanning effect is not established.
No. A cultured human cell is an experimental model, not a patient receiving the product.
No. It used a targeted oral formulation in mice, with different delivery and exposure.
The blend proposes combining its inflammatory-signalling research with other repair-related components. Combination efficacy has not been established.
Recovery & Repair
Recovery & Repair
Recovery & Repair
Recovery & Repair